Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH1 | Q92800 | 12/20 | 0.77 |
| ▸ | EZH2 | Q15910 | 12/20 | 0.77 |
| ▸ | EED | O75530 | 3/20 | 0.77 |
| ▸ | RBBP4 | Q09028 | 3/20 | 0.77 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.77 |
| ▸ | RBBP7 | Q16576 | 3/20 | 0.77 |
| ▸ | AEBP2 | Q6ZN18 | 3/20 | 0.77 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.77 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.77 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21271628 | 1.00 | EZH1 (0.77) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL30122954 | 0.95 | EZH1 (0.75) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL21271698 | 0.95 | EZH1 (0.75) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL21271624 | 0.93 | EZH2 (0.82) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL30123418 | 0.93 | EZH2 (0.82) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL28996183 | 0.91 | EZH2 (0.71) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL21271679 | 0.90 | EZH2 (0.87) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL30122737 | 0.90 | EZH2 (0.87) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL21271693 | 0.88 | EZH2 (0.78) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL30122873 | 0.88 | EZH2 (0.78) | EZH1EZH2EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH1 2/4885EZH2 1/4885EED 3/4885 |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH1 2/4885EZH2 1/4885EED 3/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH1 2/4885EZH2 1/4885EED 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.